Company profile
AAVantgarde Bio company profile
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders. Its platform addresses a major limitation in traditional AAV (adeno-associated virus) gene delivery by enabling the packaging and delivery of large genes that exceed the usual vector capacity. The company’s two lead programs are AAVB-039, targeting Stargardt disease caused by ABCA4 mutations, and AAVB-081, for Usher syndrome type 1B (Usher 1B), affecting vision and hearing.
Business identity
- Website
- https://www.aavantgarde.com/
- Contact email
- [email protected]
- Phone number
- +39 329-552-4297
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00011-00050 employees
- Revenue range
- $1K+
- Founded
- 2021-01-01
Headquarters
- Headquarters
- Pegola, Emilia-Romagna, Italy
- Postal code
- 20122
- Country code
- IT
- Continent
- Europe